On October 18, 2024, Matthew Sippel, Director at Korea Fund Inc (KF, Financial), purchased 2,000 shares of the company, as reported in a recent SEC Filing. This transaction increased the insider's holdings to 2,000 shares.
Korea Fund Inc (KF, Financial) is an investment fund that focuses on investments in Korean equities, aiming to provide investors with long-term capital appreciation. The fund invests in a diversified portfolio of Korean securities.
The shares were bought at a price of $22.33 each, valuing the transaction at $44,660. Following this purchase, the market cap of Korea Fund Inc stands at $106.813 million.
The company's current price-earnings ratio is 10.21, which is below both the industry median of 11.82 and the historical median for the company. This valuation metric is a critical indicator used by investors to gauge the company's profitability relative to its share price.
Insider transactions can provide valuable insights into a company's health and management's confidence in the firm's prospects. The recent purchase by the insider might suggest a positive outlook on the company's future performance.
Over the past year, there has been a total of 1 insider buy and 0 insider sells for Korea Fund Inc. The insider's recent acquisition marks a continued interest in increasing their stake in the company.
For more detailed information on Korea Fund Inc's valuation metrics such as price-sales ratio, price-book ratio, and price-to-free cash flow, investors can refer to the GF Value for a comprehensive analysis.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
